504
Views
0
CrossRef citations to date
0
Altmetric
Epidemiology, Genetics & Genomic

A novel mutation in the tropomyosin 1 gene in a Chinese patient with hypertrophic cardiomyopathy

ORCID Icon, , , , , , , & ORCID Icon show all
Pages 1264-1272 | Received 07 Oct 2021, Accepted 26 Oct 2022, Published online: 08 Dec 2022

References

  • Brown JH, Zhou Z, Reshetnikova L, Robinson H, Yammani RD, Tobacman LS, Cohen C. 2005. Structure of the mid-region of tropomyosin: bending and binding sites for actin. Proc Natl Acad Sci U S A. 102(52):18878–18883. doi:10.1073/pnas.0509269102.
  • Carlus SJ, Almuzaini IS, Karthikeyan M, Loganathan L, Al-Harbi GS, Carlus FH, Al-Mazroea AH, Morsy MM, Abo-Haded HM, Abdallah AM, Al-Harbi KM. 2020. A novel homozygous TPM1 mutation in familial pediatric hypertrophic cardiomyopathy and in silico screening of potential targeting drugs. Eur Rev Med Pharmacol Sci. 24(14):7732–7744. doi:10.26355/eurrev_202007_22299.
  • de Noronha SV, Sharma S, Papadakis M, Desai S, Whyte G, Sheppard MN. 2009. Aetiology of sudden cardiac death in athletes in the United Kingdom: a pathological study. Heart. 95(17):1409–1414. doi:10.1136/hrt.2009.168369.
  • Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, et al. 2014. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 35(39):2733–2779. doi:10.1093/eurheartj/ehu284.
  • England J, Granados-Riveron J, Polo-Parada L, Kuriakose D, Moore C, Brook JD, Rutland CS, Setchfield K, Gell C, Ghosh TK, et al. 2017. Tropomyosin 1: Multiple roles in the developing heart and in the formation of congenital heart defects. J Mol Cell Cardiol. 106:1–13. doi:10.1016/j.yjmcc.2017.03.006.
  • Hensley N, Dietrich J, Nyhan D, Mitter N, Yee MS, Brady M. 2015. Hypertrophic cardiomyopathy: a review. Anesth Analg. 120(3):554–569. doi:10.1213/ANE.0000000000000538.
  • Jagatheesan G, Rajan S, Ahmed RP, Petrashevskaya N, Boivin G, Arteaga GM, Tae HJ, Liggett SB, Solaro RJ, Wieczorek DF. 2010. Striated muscle tropomyosin isoforms differentially regulate cardiac performance and myofilament calcium sensitivity. J Muscle Res Cell Motil. 31(3):227–239. doi:10.1007/s10974-010-9228-3.
  • Kalayinia S, Goodarzynejad H, Maleki M, Mahdieh N. 2018. Next generation sequencing applications for cardiovascular disease. Ann Med. 50(2):91–109. doi:10.1080/07853890.2017.1392595.
  • Marian AJ. 2021. Molecular genetic basis of hypertrophic cardiomyopathy. Circ Res. 128(10):1533–1553. doi:10.1161/CIRCRESAHA.121.318346.
  • Maron BJ. 2018. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 379(7):655–668. doi:10.1056/NEJMra1710575.
  • Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. 2009. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 119(8):1085–1092. doi:10.1161/CIRCULATIONAHA.108.804617.
  • Maron BJ, Maron MS. 2013. Hypertrophic cardiomyopathy. Lancet. 381(9862):242–255. doi:10.1016/S0140-6736(12)60397-3.
  • Maron BJ, Maron MS, Semsarian C. 2012. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 60(8):705–715. doi:10.1016/j.jacc.2012.02.068.
  • Nakajima-Taniguchi C, Matsui H, Nagata S, Kishimoto T, Yamauchi-Takihara K. 1995. Novel missense mutation in α-tropomyosin gene found in Japanese patients with hypertrophic cardiomyopathy. J Mol Cell Cardiol. 27(9):2053–2058. doi:10.1016/0022-2828(95)90026-8.
  • Patil A, Nakai K, Nakamura H. 2011. HitPredict: a database of quality assessed protein-protein interactions in nine species. Nucleic Acids Res. 39(Database issue):D744–D749. doi:10.1093/nar/gkq897.
  • Petrovski S, Aggarwal V, Giordano JL, Stosic M, Wou K, Bier L, Spiegel E, Brennan K, Stong N, Jobanputra V, et al. 2019. Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study. Lancet. 393(10173):758–767. doi:10.1016/S0140-6736(18)32042-7.
  • Sabater-Molina M, Perez-Sanchez I, Hernandez Del Rincon JP, Gimeno JR. 2018. Genetics of hypertrophic cardiomyopathy: A review of current state. Clin Genet. 93(1):3–14. doi:10.1111/cge.13027.
  • Teekakirikul P, Zhu W, Huang HC, Fung E. 2019. Hypertrophic cardiomyopathy: an overview of genetics and management. Biomolecules. 9(12). doi:10.3390/biom9120878.
  • Thierfelder L, MacRae C, Watkins H, Tomfohrde J, Williams M, McKenna W, Bohm K, Noeske G, Schlepper M, Bowcock A, et al. 1993. A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc Natl Acad Sci U S A. 90(13):6270–6274. doi:10.1073/pnas.90.13.6270.
  • Tian Z, Zeng Y, Cheng KA, Gao P, Zhao DC, Cui QC, Jiang XC, Chen LF, Fang Q. 2010. Importance of endomyocardial biopsy in unexplained cardiomyopathy in China: a report of 53 consecutive patients. Chin Med J. 123(7):864–870.
  • Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. 2020. Hypertrophic cardiomyopathy: the future of treatment. Eur J Heart Fail. 22(2):228–240. doi:10.1002/ejhf.1715.
  • Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT, de Beer TAP, Rempfer C, Bordoli L, et al. 2018. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 46(W1):W296–W303. doi:10.1093/nar/gky427.
  • Watkins, H., Anan, R., Coviello, D.A., Spirito, P., Seidman, J.G., Seidman, C.E., 1995. A De novo mutation in α-tropomyosin that causes hypertrophic cardiomyopathy. Circulation 91(9), 2302-2305. doi:10.1161/01.CIR.91.9.2302.
  • Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK. 2019. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 10(1):1523. doi:10.1038/s41467-019-09234-6.
  • Zou Y, Song L, Wang Z, Ma A, Liu T, Gu H, Lu S, Wu P, Zhang dagger Y, Shen dagger L, et al. 2004. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med. 116(1):14–18. doi:10.1016/j.amjmed.2003.05.009.